Last updated: February 20, 2026
What is NDC 00121-0777?
NDC 00121-0777 refers to Nusinersen (Spinraza), marketed by Biogen. It is approved for treating spinal muscular atrophy (SMA) in pediatric and adult patients.
Market Size and Growth Drivers
- Prevalence of SMA: Estimated at 1 in 10,000 live births. Approximately 15,000 patients in the U.S. may be eligible for treatment (source: SMA Foundation).
- Current Treatments: Spinraza remains the only FDA-approved antisense oligonucleotide for SMA until recently challenged by gene therapies.
- Market Expansion: Biogen’s product faces competition from gene therapies such as Novartis’ Zolgensma, approved in 2019.
- Pipeline Developments: Emerging therapies and biosimilars could influence pricing and market share.
Market Revenue and Penetration
| Year |
Estimated U.S. Sales |
Global Sales |
Key Drivers |
| 2022 |
$1.4 billion |
$1.6 billion |
Growing diagnosis rate, expanded indications |
| 2023 |
$1.6 billion |
$1.8 billion |
Broader insurance coverage, more approval for older patients |
| 2024 |
$1.9 billion |
$2.1 billion |
Increased adoption in early-stage SMA |
These figures are derived from BI data, market analyst projections, and sales reports (source: Evaluate Pharma).
Pricing Details
- Initial Launch Price: Approx. $125,000 per injection.
- Annual Cost: Roughly $750,000 to $950,000 per patient; based on average dosing schedules (monthly injections for 14 months then maintenance).
- Cost Adjustments: Price decreases observed in certain markets due to biosimilar entry and negotiated discounts.
Price Comparison with Competitors
| Drug |
Treatment Cost |
Administration |
Approval Year |
Market Share (2023) |
| Spinraza (Nusinersen) |
~$750,000–$950,000/year |
Intrathecal injections |
2016 |
65% in SMA therapy market (US) |
| Zolgensma |
~$2.1 million one-time |
One-time infusion |
2019 |
30% in SMA market (US) |
| Evrysdi (risdiplam) |
~$340,000/year |
Oral |
2020 |
Emerging, 5% market share |
Price Projections (2023-2027)
| Year |
Estimated Average Price |
Factors Influencing Price |
| 2023 |
$750,000 |
Maintain current pricing; discounts via payer negotiations and biosimilars' entry. |
| 2024 |
$700,000 |
Slight decline expected due to biosimilar development and competitive pressure. |
| 2025 |
$650,000 |
Potential further reductions as biosimilar-like drugs and new therapies gain approval. |
| 2026 |
$600,000 |
Expected stabilization; increased use of oral therapies may impact injections. |
| 2027 |
$550,000 |
Market saturation and increased competition drive prices downward. |
Regulatory and Policy Impact
- Patent Expiry & Biosimilar Entry: Biosimilars could enter as early as 2027, pressuring prices.
- Value-Based Pricing: Emerging models tying reimbursement to patient outcomes could lead to discounts.
- Pricing Regulations: Increased scrutiny over high-cost biologics may influence future pricing.
Key Takeaways
- Spinraza remains a dominant SMA therapy with US sales exceeding $1.4 billion in 2022.
- Pricing is high, roughly $750,000 annually per patient, but expected to decline gradually due to biosimilar competition and market dynamics.
- Competition from gene therapy Zolgensma and oral risdiplam poses a threat to market share and pricing.
- Market expansion into adult SMA and off-label use will influence revenue growth.
- Regulatory pathways and biosimilar approvals will shape future pricing and market share.
FAQs
1. How does Spinraza compare to Zolgensma in efficacy?
Spinraza requires multiple injections over time, whereas Zolgensma is a one-time gene therapy. Efficacy varies by patient, with Zolgensma showing rapid improvement in infants.
2. What impact will biosimilars have on Spinraza's price?
Biosimilars could reduce prices by 20-40%, depending on market acceptance and competition intensity.
3. Are there emerging treatments that could replace Spinraza?
Yes, oral drugs like Evrysdi have gained market share due to ease of administration. Ongoing trials are exploring newer gene editing therapies.
4. How is reimbursement for Spinraza structured?
Reimbursement is negotiated through payers, often tied to prior authorization, outcomes, and discounts.
5. What are the key regulatory risks for Spinraza?
Regulatory challenges include patent disputes, biosimilar approval pathways, and pricing regulation pressures.
References
- Evaluate Pharma. (2023). 2023 World Preview: Market Forecasts and Analysis.
- U.S. Food and Drug Administration (FDA). (2016). Spinraza approval announcement.
- SMA Foundation. (2022). SMA prevalence and treatment landscape.
- Biogen. (2023). Spinraza sales reports.
- Novartis. (2023). Zolgensma market performance data.
